R L Comenzo
Overview
Explore the profile of R L Comenzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong S, Larivee D, Warner M, Sprague K, Fogaren T, Comenzo R
Bone Marrow Transplant
. 2017 Apr;
52(6):936-937.
PMID: 28394371
No abstract available.
2.
Landau H, Smith M, Landry C, Chou J, Devlin S, Hassoun H, et al.
Leukemia
. 2016 Aug;
31(1):136-142.
PMID: 27560108
Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan...
3.
Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz M, Grogan M, et al.
Leukemia
. 2016 Jul;
30(10):1979-1986.
PMID: 27416985
Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs,...
4.
Ma X, Zhou P, Wong S, Warner M, Chaulagain C, Comenzo R
Gene Ther
. 2016 Jul;
23(10):727-733.
PMID: 27383253
Treatment of light chain (LC) deposition diseases both nonfibrillar and fibrillar is aimed at eliminating LC production but success is limited. We report on the testing of an small interfering...
5.
Kaul E, Shah G, Chaulagain C, Comenzo R
Bone Marrow Transplant
. 2014 Jun;
49(9):1233.
PMID: 24933207
No abstract available.
6.
Landau H, Hassoun H, Rosenzweig M, Maurer M, Liu J, Flombaum C, et al.
Leukemia
. 2012 Sep;
27(4):823-8.
PMID: 23014566
To improve the efficacy of risk-adapted melphalan (MEL) in patients with amyloidosis (AL), we conducted a phase II trial using bortezomib and dexamethasone (BD) as consolidation. Forty untreated patients with...
7.
Rosenzweig M, Landau H, Seldin D, OHara C, Girnius S, Hanson N, et al.
Blood Cancer J
. 2012 Sep;
2:e90.
PMID: 22983433
Light-chain amyloidosis (AL) is a plasma cell dyscrasia closely related to multiple myeloma. In multiple myeloma, the cancer-testis antigens (CTAs) CT7 (MAGE-C1), CT10 (MAGE-C2) and MAGE-A CTAs are expressed in...
8.
Comenzo R, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al.
Leukemia
. 2012 Apr;
26(11):2317-25.
PMID: 22475872
This manuscript summarizes the recommendations that emerged from the first Roundtable on Clinical Research in Immunoglobulin Light-chain Amyloidosis (AL), a meeting sponsored by the Amyloidosis Foundation (Clarkston, MI, USA) to...
9.
Dubrey S, Comenzo R
QJM
. 2012 Jan;
105(7):617-31.
PMID: 22223674
Amyloid diseases in man are caused by as many as 23 different pre-cursor proteins already described. Cardiologists predominantly encounter three main types of amyloidosis that affect the heart: light chain...
10.
Landau H, Hassoun H, Bello C, Hoover E, Riedel E, Nimer S, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:135-6.
PMID: 21838462
No abstract available.